Skip to main content
VCbacked
Log inGet Started

ROME Therapeutics

Cambridge, United States

ROME Therapeutics is developing novel therapies for cancer and autoimmune diseases by harnessing the power of the repeatome.

$72.0M raised
Sep 2023
Series B
BiotechnologyHealth CarePharmaceutical

Top Investors

Andreessen HorowitzS32ARCH Venture PartnersBristol-Myers SquibbAlexandria Venture Investments

Founder Contacts

19,000+ verified contacts
Get Instant Access

Emails, phones & LinkedIn profiles

Frequently Asked Questions about ROME Therapeutics

How much funding has ROME Therapeutics raised?
ROME Therapeutics has raised $72.0M in total funding. The most recent round was Series B. The last funding was announced in September 2023.
Who are ROME Therapeutics's investors?
ROME Therapeutics's investors include Andreessen Horowitz, S32, ARCH Venture Partners, Bristol-Myers Squibb, Alexandria Venture Investments.
Where is ROME Therapeutics headquartered?
ROME Therapeutics is headquartered in Cambridge, United States.
What does ROME Therapeutics do?
ROME Therapeutics is developing novel therapies for cancer and autoimmune diseases by harnessing the power of the repeatome.
What stage is ROME Therapeutics at?
ROME Therapeutics is at the Series B stage.
Cite this page

Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .

MLA
"ROME Therapeutics — Funding & Investors." VCBacked, September 12, 2023, https://www.vcbacked.co/company/rome-therapeutics. Accessed June 4, 2026.
APA
VCBacked. (2023). ROME Therapeutics — Funding & Investors. Retrieved June 4, 2026, from https://www.vcbacked.co/company/rome-therapeutics
Wikipedia (cite web)
{{cite web |title=ROME Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/rome-therapeutics |website=VCBacked |access-date=June 4, 2026}}

Profile data sourced and verified per the VCBacked methodology. Last funding round dated .

Similar Companies in Biotechnology

View all
Virtuoso Surgical
Nashville
Pharvaris
Zug
Odyssey Therapeutics
Boston$213.0M
Tempus
Chicago
Anagram Therapeutics
Boston
Prenetics
Hong Kong